Cannabis Stocks

Marijuana Investors Bet Big On Long-Term Growth Over Short-Term Earnings As Market Value Rises By 39%
Gold Flora's Strategic Cannabis Blueprint: 30% In-House Sales Boost, Profits, EBITDA Rise
Mortgage And Property Finance Giant's $354M Portfolio: Growth Amid Cannabis Sector Volatility
Gold Flora's Strategic Cannabis Blueprint: 30% In-House Sales Boost, Profits, EBITDA Rise
Mortgage And Property Finance Giant's $354M Portfolio: Growth Amid Cannabis Sector Volatility
Cannabis Market's Trading Volume Surges Up 292%, Viridian Capital Highlights Mixed Liquidity
This Dividend-Paying Cannabis Stock Had Higher 1-Year Return Than Tesla, Citigroup, Apple And Zillow

Cannabis Stocks Recent News

Heritage Cannabis' Stock Plunges On Announcing Creditor Protection, Looks To Pursue Restructuring And Sales Process
Heritage Cannabis Holdings Corp. announced on Tuesday that alongside its subsidiaries it sought and obtained an order for creditor protection from the Ontario Superior Court of Justice under the Companies Creditors Arrangement Act. "The difficult but necessary decision to commence CCAA proceedings was made after careful consideration of the Company's financial position while evaluating all available alternatives and engaging in significant consultation with legal and financial advisors," the company said in a press release. The Toronto-based cannabis producer also said that BJK Holdings Ltd., its senior secured lender, made a demand to the company for payment in full of certain indebtedness owing by the Heritage Group to the lender totaling $8,421,088.87. Heritage has entered into binding agreements to sell its real estate properties in Ontario and British Columbia to BJK Developments Ltd. for a net purchase price of $9,714,475 and lease the Ontario and BC Property back from the purchaser in October. The company said at the time the purchase would be used to set off the amount owing by the company to its lender, BJK Holdings Ltd., a related entity of the purchaser, reducing the company's remaining term debt by roughly 64% to $5,256,379. The remaining term financing, as amended within a third amending agreement, has been extended through to Jan. 31, 2025. Additionally, the company said it retains its revolving line of credit of up to $5 million with BJK, which has also been extended until the same date.
Green Gold Rush: Here's What's Driving Cannabis Stocks Higher
Various themes and sectors garnered buzz and attention as the first quarter drew to a close. However, one industry that has been in a lull for a significant period reignited the imagination and hope of longstanding investors after it finished the first quarter in style. 
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.
California's Weed Sales Decline: Market Ripe For Consolidation, Biggest Companies Likely To Benefit
The California cannabis sector is facing a sales decline, according to a recent market update from Pablo Zuanic, senior equity research analyst at Zuanic & Associates.
Cannabis Stocks Set To Dominate Germany's New Market: A Surge In Demand Meets Established Expertise
Germany's historic step towards cannabis legalization, effective April 1, 2024, opens a new chapter in the global cannabis industry, presenting substantial opportunities for Canadian leaders Aurora (NASDAQ: ACB), Canopy Growth (NASDAQ: CGC), and Tilra
How Did MariMed Cannabis Company's Revenue Surge By 48%? Find Out At Benzinga Cannabis Capital Conference
MariMed, Inc. has embarked on a remarkable journey, boasting a 48% increase in wholesale revenue in 2023 and projecting over 20% growth for 2024. Under the leadership of CEO Jon Levine, the company has navigated through regulatory uncertainties and competitive market headwinds with strategic expansions and product innovation.
VP Harris, DEA, FDA Eye Cannabis: Key Changes Ahead, Here's What One Expert Predicts
Vice President Harris's urgent call to the DEA to expedite the rescheduling of cannabis marks a crucial turning point in national drug policy, as analyzed in a comprehensive equity research report by Zuanic & Associates.
Inflation Rattles Markets Ahead Of Fed Meeting; AI Stocks, Crypto Pause As Gold, Oil Advance: This Week In The Markets
Inflation reports unveiled in the week preceding the Fed meeting brought an unwelcome news to investors.
Cannabis Stocks Jump On News That DEA May Soon Undertake Marijuana Reform
Doug Kass, world-renowned hedge fund manager, posted on X, formerly Twitter, Friday that the "DEA will approve a rescheduling of cannabis to Schedule III." 
Jushi Beats All Expectations: Cannabis Company Surpasses Analysts' 4Q23 Sales And Profit Forecasts
The multi-state cannabis company Jushi Holdings (OTC: JUSHF), reported a significant increase in unique patient visits in Virginia, indicating robust growth in the fourth quarter of 2023.
NASDAQ-Listed Village Farms Grabs #2 Spot In Canada's Cannabis Market: What's Its Winning Formula?
Cannabis company Village Farms International, Inc. (NASDAQ: VFF) is making noteworthy strides, securing the #2 position in the recreational cannabis market in Canada.
Green Thumb's Edge Over S&P 500 & ETFs: Cannabis Investor Confidence Propels Expansion Into Key States
Green Thumb Industries Inc. (OTC: GTBIF) is ramping up investments across Minnesota, Ohio, Virginia, Florida and Pennsylvania to gear up for recreational marijuana legalization.
Marijuana Company Verano Holdings Worth $2.1B, Outprices Its Expected 2024 Earnings
Despite facing retail pressures, especially in New Jersey, which is leading to an expected 5-7% dip in Q1 2024 sales, Verano Holdings (OTC: VRNOF) is still poised for growth, says senior analyst Pablo Zuanic.
Curaleaf Price Target Spikes, Fueled By German Cannabis Legalization Changes — ROTH MKM Explains
Strategic Outlook And Earnings Forecast
All You Need To Know About The German Marijuana Market: Changes, Size And Leading Players
Senior analyst Pablo Zuanic of Zuanic & Associates outlines the transformative potential of new legislation in Germany's medical cannabis sector, forecasting market growth from a 28,000 patient base in 2023 to a value of €1.7 billion by 2025.
Cannabis Stocks Gear Up For Germany's New Market: Check Out Who's Set To Win Big
While there are still very few medical marijuana patients in Germany, with the new regulations, there is enormous growth potential. Canadian exporters Tilray and Aurora, says analyst, are among the best positioned to benefit as they are already major players in Germany.
[Video] Cannabis Industry's 2024 Outlook: Expert Analysis From Highway 33 Capital Advisory
Jushi Holdings Revs Up, Unleashing Torque In Pennsylvania And Virginia's Cannabis Expansion
In a recent comprehensive analysis by senior analyst Pablo Zuanic of Zuanic & Associates, Jushi Holdings (OTC: JUSHF) stands out as a multi-state operator (MSO) with significant market cap upside potential, particularly from developments in Pennsylvania and Virginia.
This Cannabis Stock Is Undervalued, Says Top Analyst: Why Jushi Has An Edge In The Market
Zuanic & Associates gave Jushi Holdings Inc. (CSE: JUSH) (OTC: JUSHF) an Overweight rating as the firm begins its coverage of the marijuana company.
Village Farms International Sustains High Cannabis EBITDA Margins, Setting Stage For Growth, Market Research Shows
With the cannabis sector experiencing dynamic shifts, Village Farms International (NASDAQ: VFF) emerges as a key player, poised for significant growth.
Flip Your Pre-Roll: 50-50 Odds It's Crafted By This Weed Company Dominating Half Of Canada's Market
In Canada, there's a 50-50 chance that the pre-roll lighting up your day is made by one company: Decibel. Infused pre-rolls have ignited a fiery growth trend, with Decibel stoking the flames and reigning supreme as the king of pre-rolls.
Cannabis Stocks And ETFs Trading Higher As Government Recommendations Ignite Hope For Industry
Cannabis stocks and ETFs opened higher on Tuesday following the release of documents related to the Department of Health and Human Service's (HHS) review of cannabis. Investors are optimistic about potential regulatory changes that could benefit the cannabis industry after the US government released 252 pages of documents confirming the HHS's recommendation that the DEA reschedule cannabis as Schedule III under the Controlled Substances Act. The documents state that cannabis has a currently accepted medical use in treatment and potential for abuse less than drugs in Schedules I and II. In August, the Assistant Secretary for Health wrote a letter to the DEA calling for marijuana to be reclassified. The Secretary of HHS has confirmed that his department shared a comprehensive scientific review with the DEA in response to President Joe Biden's scheduling directive.
Why Is My Screen So Green? Cannabis Stocks Surge In Early 2024, WTR Reports Findings
In early 2024, the screens of cannabis investors lit up with a promising green glow, which signals stock prices going up and a bullish surge in cannabis stocks.